• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病的组织学评估

Histological assessment of non-alcoholic fatty liver disease.

作者信息

Hübscher S G

机构信息

Department of Pathology, University of Birmingham, Birmingham, UK.

出版信息

Histopathology. 2006 Nov;49(5):450-65. doi: 10.1111/j.1365-2559.2006.02416.x.

DOI:10.1111/j.1365-2559.2006.02416.x
PMID:17064291
Abstract

Non-alcoholic fatty liver disease (NAFLD) is an important complication of the metabolic syndrome, which is becoming an increasingly common cause of chronic liver disease. Histological changes typically mainly affect perivenular regions of the liver parenchyma and include an overlapping spectrum of steatosis, steatohepatitis and persinusoidal or pericellular fibrosis, in some cases leading to cirrhosis. Once cirrhosis has developed, typical hepatocellular changes are often no longer conspicuous, leading to such cases being mistakenly diagnosed as 'cryptogenic'. Portal inflammation, ductular reaction and periportal fibrosis can also be seen as part of the morphological spectrum of NAFLD, particularly in the paediatric population. Hepatocellular carcinoma has also been described as a complication of NAFLD-associated cirrhosis. NAFLD is also an important cofactor in other chronic liver diseases, especially hepatitis C. Histological assessments have an important role to play in the diagnosis and management of NAFLD. These include making the potentially important distinction between simple steatosis and steatohepatitis and providing pointers to the aetiology, including cases where a dual pathology exists. A number of systems have been devised for grading and staging the severity of fatty liver disease. These require further evaluation, but have a potentially important role to play in determining prognosis and monitoring therapeutic responses.

摘要

非酒精性脂肪性肝病(NAFLD)是代谢综合征的一种重要并发症,正日益成为慢性肝病的常见病因。组织学改变通常主要影响肝实质的小叶中央静脉周围区域,包括脂肪变性、脂肪性肝炎以及窦周或细胞周围纤维化等一系列重叠的病变,在某些情况下可导致肝硬化。一旦发展为肝硬化,典型的肝细胞改变往往不再明显,导致此类病例被误诊为“隐源性”。门管区炎症、小胆管反应和门管区周围纤维化也可视为NAFLD形态学谱的一部分,尤其是在儿童人群中。肝细胞癌也被描述为NAFLD相关肝硬化的一种并发症。NAFLD也是其他慢性肝病(尤其是丙型肝炎)的重要辅助因素。组织学评估在NAFLD的诊断和管理中发挥着重要作用。这些评估包括对单纯脂肪变性和脂肪性肝炎进行潜在的重要区分,并为病因提供线索,包括存在双重病理的情况。已经设计了一些系统用于对脂肪性肝病的严重程度进行分级和分期。这些系统需要进一步评估,但在确定预后和监测治疗反应方面可能发挥重要作用。

相似文献

1
Histological assessment of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的组织学评估
Histopathology. 2006 Nov;49(5):450-65. doi: 10.1111/j.1365-2559.2006.02416.x.
2
Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications.综述文章:非酒精性脂肪性肝病与丙型肝炎——危险因素及临床意义
Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:48-51. doi: 10.1111/j.1365-2036.2005.02596.x.
3
[Non-alcoholic fatty liver disease--new view].[非酒精性脂肪性肝病——新视角]
Pol Merkur Lekarski. 2008 Jun;24(144):568-71.
4
Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD.通过形态计量学测量的脂肪变性程度与 NAFLD 患者的其他肝脏病变和代谢综合征成分有关。
Eur J Gastroenterol Hepatol. 2011 Nov;23(11):974-81. doi: 10.1097/MEG.0b013e32834a4d82.
5
Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.非酒精性脂肪性肝病/非酒精性脂肪性肝炎:组织学诊断标准及评分系统。
Eur J Gastroenterol Hepatol. 2010 Jun;22(6):643-50. doi: 10.1097/MEG.0b013e32832ca0cb.
6
Spectrum of histological features in non-alcoholic fatty liver disease.非酒精性脂肪性肝病的组织学特征谱
Natl Med J India. 2007 Nov-Dec;20(6):282-7.
7
Pathologic assessment of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的病理评估
Clin Liver Dis. 2007 Feb;11(1):17-23, vii. doi: 10.1016/j.cld.2007.02.002.
8
The comparison of scoring scales for liver biopsy assessment in morbidly obese patients undergoing bariatric surgery.接受减肥手术的病态肥胖患者肝脏活检评估评分量表的比较。
Obes Surg. 2005 Oct;15(9):1309-14. doi: 10.1381/096089205774512582.
9
[Non-alcoholic fatty liver].[非酒精性脂肪肝]
Rev Gastroenterol Peru. 2003 Jan-Mar;23(1):49-57.
10
Nonalcoholic fatty liver disease (NAFLD): a comprehensive review.非酒精性脂肪性肝病(NAFLD):综述
J Insur Med. 2004;36(1):27-41.

引用本文的文献

1
Hepatic progenitor cell activation and ductular reaction in metabolic dysfunction-associated steatotic liver disease (MASLD): Indicators for disease activity and the degree of fibrosis: The pilot study.代谢功能障碍相关脂肪性肝病(MASLD)中的肝祖细胞激活与小胆管反应:疾病活动度和纤维化程度的指标:一项初步研究
Medicine (Baltimore). 2025 Apr 11;104(15):e42108. doi: 10.1097/MD.0000000000042108.
2
Clinical associations of portal-based disease in MASLD: proposal of a new histological scoring system.非酒精性脂肪性肝病门静脉相关疾病的临床关联:一种新的组织学评分系统的提议
Virchows Arch. 2025 Apr 10. doi: 10.1007/s00428-025-04087-5.
3
Postpartum development of metabolic dysfunction-associated steatotic liver disease in a lean mouse model of gestational diabetes mellitus.
妊娠糖尿病瘦鼠模型中代谢功能障碍相关脂肪性肝病的产后发病情况。
Sci Rep. 2024 Jun 25;14(1):14621. doi: 10.1038/s41598-024-65239-2.
4
Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges.非酒精性脂肪性肝病患者的门静脉高压:当前认知与挑战
World J Gastroenterol. 2024 Jan 28;30(4):290-307. doi: 10.3748/wjg.v30.i4.290.
5
Neutrophils: tissue and circulating signatures of pediatric non-alcoholic fatty liver disease.中性粒细胞:儿童非酒精性脂肪性肝病的组织和循环特征
Front Cell Dev Biol. 2024 Jan 4;11:1336033. doi: 10.3389/fcell.2023.1336033. eCollection 2023.
6
Relative Recovery of Non-Alcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Rats.饮食诱导肥胖大鼠中非酒精性脂肪肝(NAFLD)的相对恢复。
Nutrients. 2023 Dec 28;16(1):115. doi: 10.3390/nu16010115.
7
The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression.遗传背景影响对线粒体功能障碍和 NASH 进展的易感性。
J Exp Med. 2023 Apr 3;220(4). doi: 10.1084/jem.20221738. Epub 2023 Feb 14.
8
Granulocytic MDSC with Deficient CCR5 Alleviates Lipogenesis and Inflammation in Nonalcoholic Fatty Liver Disease.粒细胞 MDSC 表达缺陷的 CCR5 减轻非酒精性脂肪性肝病的脂生成和炎症反应
Int J Mol Sci. 2022 Oct 27;23(21):13048. doi: 10.3390/ijms232113048.
9
Covalent Inhibition of Pyruvate Kinase M2 Reprograms Metabolic and Inflammatory Pathways in Hepatic Macrophages against Non-alcoholic Fatty Liver Disease.共价抑制丙酮酸激酶 M2 重塑肝巨噬细胞代谢和炎症途径以对抗非酒精性脂肪性肝病。
Int J Biol Sci. 2022 Aug 15;18(14):5260-5275. doi: 10.7150/ijbs.73890. eCollection 2022.
10
GVS-12 attenuates non-alcoholic steatohepatitis by suppressing inflammatory responses PPARγ/STAT3 signaling pathways.GVS-12通过抑制炎症反应的PPARγ/STAT3信号通路减轻非酒精性脂肪性肝炎。
RSC Adv. 2019 Mar 26;9(17):9555-9564. doi: 10.1039/c8ra10178g. eCollection 2019 Mar 22.